Skip to main content
HBM Holdings Limited logo

HBM Holdings Limited — Investor Relations & Filings

Ticker · 2142 ISIN · KYG4403H1002 LEI · 254900ZT5QBQG3JL9J21 HKEX Manufacturing
Open in API
Filings indexed 421 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2142

About HBM Holdings Limited

http://www.harbourbiomed.com

HBM Holdings Limited is a global biopharmaceutical company specializing in the discovery, development, and commercialization of novel antibody therapeutics. The company focuses on addressing unmet medical needs in oncology, immuno-oncology, and immunological diseases. HBM's core technological foundation is the integrated Harbour antibody platform, featuring the proprietary Harbour Mice® technology. This platform is engineered to generate highly diverse, fully human monoclonal antibodies in both the conventional two heavy/two light chain (H2L2) format and the heavy chain only (HCAb) format. Utilizing the HCAb format, HBM develops advanced next-generation biologics, including HCAb-based immune cell engagers (HBICE®). The company maintains a robust pipeline of differentiated clinical assets and actively engages in technology licensing and strategic collaborations to accelerate the development of innovative therapies.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 90% confidence The document is a ‘Next Day Disclosure Return’ filed under the Hong Kong Stock Exchange listing rules (Main Board Rule 13.25A / GEM Rule 17.27A), detailing changes in issued shares and treasury shares – specifically share repurchases (buybacks) and issuance of new shares under a share award scheme. It is not an earnings release, AGM material, or management change notice. Instead, it is an announcement of capital changes (issuance and repurchase of shares), fitting the ‘Share Issue/Capital Change’ category (SHA).
2026-05-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Stock Exchange "Next Day Disclosure Return" (Form FF305) detailing changes in issued shares and treasury shares, including on-market share repurchases, treasury share sales, and share issuances under a share award scheme. It is a regulatory filing reporting the company’s transactions in its own shares (share buybacks and treasury share movements). This fits the “Transaction in Own Shares” category (POS).
2026-05-20 English
Next Day Disclosure Return
Regulatory Filings
2026-05-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return filed under Hong Kong Stock Exchange rules, detailing changes in issued shares (including issuance under a share award scheme) and repurchases of the company’s own shares (treasury activities). It is a regulatory disclosure of transactions in the company’s own shares rather than a full report or announcement of dividends, management changes, or financial results. Therefore it best fits the “Transaction in Own Shares” category (POS).
2026-05-18 English
VOLUNTARY ANNOUNCEMENT - RELEASE OF PRECLINICAL DATA FOR LET003, FIRST AI-ENABLED DRUG CANDIDATE, A NEXT-GENERATION ACVR2A/2B-TARGETING ANTIBODY FOR OBESITY TREATMENT
Regulatory Filings Classification · 88% confidence The document is a voluntary company announcement regarding preclinical data for a new drug candidate. It is not a financial report (no financial statements), not an earnings release, not an investor presentation (no slide deck format), and not any specific corporate action (M&A, share issue, dividend, etc.). It is thus a general regulatory announcement and falls under the fallback category 'Regulatory Filings' (RNS).
2026-05-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return under the Hong Kong Stock Exchange Listing Rules (Form FF305) detailing changes in issued shares, repurchase of shares for treasury, on-market sale of treasury shares, and repurchase mandate information. This is a direct report of transactions in the company’s own shares (buy-backs and treasury movements). It fits the “Transaction in Own Shares” category.
2026-05-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.